CJC-1295 No DAC + Ipamorelin: Benefits, Dosage, Side Effects and Risks
What CJC-1295 without DAC and ipamorelin are, how the pair is meant to raise growth hormone, the research, side effects, doses and FDA status.
Peptide Profiles
All profiles →- Not FDA-approved
MOTS-c
Mitochondrial open reading frame of the 12S rRNA type-c
Mitochondrial-derived peptide (16 amino acids)
A 16-amino-acid peptide made by mitochondria. It improved metabolism and exercise capacity in mice, but has never been tested in a published human trial.
Read profile → - Not FDA-approved
NAD+
Nicotinamide adenine dinucleotide · Coenzyme I · Nadide
Coenzyme (not a peptide)
A coenzyme found in every cell, sold as IV drips and injections. Precursors like NMN and NR raise blood NAD+, but clinical benefits are inconsistent.
Read profile → - Investigational
Retatrutide
LY3437943 · "Reta"
GIP, GLP-1 and glucagon receptor triple agonist
Lilly's investigational triple agonist. In the phase 3 TRIUMPH-1 trial, the 12 mg dose produced 28.3% average weight loss at 80 weeks.
Read profile → - FDA-approved
Semaglutide
Ozempic · Wegovy · Rybelsus
GLP-1 receptor agonist
Novo Nordisk's GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and heart risk.
Read profile → - FDA-approved
Tirzepatide
Mounjaro · Zepbound · LY3298176
GIP and GLP-1 receptor dual agonist
Lilly's GIP and GLP-1 dual agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea.
Read profile →